Jan Däbritz

pediatric gastroenterologist | IBD specialist | professor | lecturer | scientist

[Jan Däbritz @JanDabritz]

Prof. Dr. Däbritz: „Die Arbeit mit Kindern macht Spaß, ist bereichernd und sehr interdisziplinär“ https://t.co/Yis52sr9t4

[JPGN @JPGNonline]

The creation of the first iteration of a pragmatic longitudinal disease burden score for pediatric #CrohnsDisease: PCD-MI (Pediatric CD Morbidity Index).

#openaccess

https://t.co/0Bz3j5W7RJ

[Jan Däbritz @JanDabritz]

Predictors of poor outcomes in #children with ulcerative colitis #IBD @APandT @GPGE_ https://t.co/N01b4vE26o

[roypounder.apt @APandT]

Now published 'open access' at https://t.co/caLQolKTt5
"Predicting complications in paediatric ulcerative colitis: A longitudinal multicentre cohort study"
#GItwitter #IBD #uc

[Jan Däbritz @JanDabritz]

B cell academy of the gut: an update on gut associated germinal centre B cell dynamics @DGKJ_eV https://t.co/yCesJAQ8zo

[John Damianos, M.D. @john_damianosMD]

ECCO guidelines on the medical management of Crohn disease

#MedTwitter #GITwitter #IBD

https://t.co/aakEekY7qy

[Jan Däbritz @JanDabritz]

Therapeutic drug monitoring in pediatric #IBD 📈📉 @DDWMeeting #DDW2024

[Jan Däbritz @JanDabritz]

21st century trends in pediatric #IBD by @ericbenchimol @DDWMeeting

👉🏻 New epidemiology insights
👉🏻 Mental health implications
👉🏻 Better use of anti-TNF
👉🏻 Dual advanced therapy
👉🏻 HLA-DQA1*05 pharmacogenomics
👉🏻 mIBD REPORT standards
👉🏻 Drug development
👉🏻 Research priorities

[Jan Däbritz @JanDabritz]

Use of concomitant medications in #children with #IBD @DDWMeeting #DDW2024

[Jan Däbritz @JanDabritz]

Calprotectin and platelet count predict histologic disease activity in #children with ulcerative colitis #IBD @EurJPediatrics @GPGE_
https://t.co/Aopr0qAuVk

[Jan Däbritz @JanDabritz]

Health Literacy of Children and Adolescents with #IBD and their parents - Coping and Information Needs https://t.co/aSsEZIGGnK #mdpichildren via @MDPIOpenAccess @DCCV_Germany

[Jan Däbritz @JanDabritz]

Efficacy and Safety Data of Risankizumab and Upadacitinib in pediatric #IBD #ECCO

[JAMA Dermatology @JAMADerm]

The risk of new-onset inflammatory bowel disease appears to be higher in children and adults with atopic dermatitis, and the risk varies based on age, atopic dermatitis severity, and subtype of inflammatory bowel disease. https://t.co/9REIa3mPKT

[Jan Däbritz @JanDabritz]

A Nationwide Survey on Patient Empowerment in Pediatric Inflammatory Bowel Disease in Germany https://t.co/xW7eSHrEi7 #mdpichildren via @MDPIOpenAccess @DCCV_Germany @GPGE_

[Jan Däbritz @JanDabritz]

Why do we need transitional care in #IBD? @hankjeescher @my_ueg #UEGWeek @ESPGHANSociety

[Jan Däbritz @JanDabritz]

Is intestinal #ultrasound the optimal tool for tight monitoring in #IBD? #UEGWeek @BowelUltrasound @my_ueg #IngestTheBest

[Jan Däbritz @JanDabritz]

Precision nutrition in #IBD #UEGWeek #IngestTheBest @my_ueg

[Jan Däbritz @JanDabritz]

@Axel_Stg @ProfWhelan @my_ueg https://t.co/K078YTl4in

[Jan Däbritz @JanDabritz]

Is diet in #IBD ready to deliver? #UEGWeek @ProfWhelan @my_ueg

[Jan Däbritz @JanDabritz]

What’s the future of #IBD super surgery? #UEGWeek @WBemelman @my_ueg

[Jan Däbritz @JanDabritz]

Will the newer #IBD agents replace TNF blockers? #UEGWeek @SeverineVermei1 @my_ueg